Abstract
INTRODUCTION
The American Cancer Society estimates that there will be nearly 300000 new breast cancer cases diagnosed worldwide and approximately 50000 women will die from breast cancer in 2016 [1] . Triple negative breast cancer (TNBC) accounts for 15% of all breast cancer diagnoses. TNBC is a subtype of breast cancer chara cterized by the lack of expression of the estrogen rece ptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor2 (HER2) [1, 2] . Due to the absence of receptor expression; this form of breast cancer, which predominantly affects younger, African American and Hispanic patients lacks targeted therapeutic options [3] . TNBC patients are commonly treated with chemotherapy; however these patients make up approximately 30% of breast cancerrelated deaths annually [4] . This necessitates the development of targeted therapies for this more aggressive form of the disease.
There are many factors that increase the risk of developing TNBC including environment, genetic susce ptibility, and obesity [5] . Obesity has a negative impact on breast cancer patient survival and, like TNBC, is associated with an increased risk of recurrence [6] .
Obesity is correlated to high levels of leptin, a cytokine produced by adipose tissue which regulates satiety. The leptin signaling pathway occurs in approximately 80% of breast cancers [7] . The binding of leptin to its receptor, ObR, leads to activation of pathways involved in cell proliferation, migration, and survival [8] . Leptin is a survival factor in breast cancer and may have the ability to limit the effectiveness of chemotherapy drugs by activating the JAK2/STAT3, MAPK/ERK, and PI3/ Akt signaling pathways [9, 10] . Therefore leptin signaling inhibition has become a promising therapeutic area for breast cancer, particularly in the case of TNBC for which there is no targeted therapy [11] . The binding of leptin to ObR upregulates Notch, interleukin 1 (IL1), vascular endothelial growth factor (VEGF), and its receptor VEGFR2; which promote breast cancer cell survival and angiogenesis [12] . The harmful effects of leptin signaling on breast cancer onset and progression have been shown to be diminished by the leptin peptide receptor antagonist 2 (LPrA2) [13] . LPrA2 and the pegylated form (PEGLPrA2) have been shown to cause a delay in cancer onset and progression as well as a reduction in 4T1tumor growth in BALB/C mice [14] . Additionally, PEGLPrA2 has been shown to decrease MDAMB231 and MCF7tumor growth in SCID mice [15] . In another study, dietinduced obese (DIO) C57BL/6J mice treated with the carcinogen 7, 12Dimethylbenz (a) anthracene (DMBA) along with PEGLPrA2 did not develop tumors [16] . The antitumor activity of LPrA2 provides mounting evidence for its usefulness in cancer therapy.
The leptin signaling pathway plays a major role in breast cancer cell growth, angiogenesis, as well as metastasis and invasion [8] . Although the leptin antagonist LPrA2 attenuates leptin signaling, it is limited by its insolubility in water and short halflife of 12 h [14, 17, 18] . Here we describe the coupling of LPrA2 to a nanoparticle delivery system which uses iron oxide nanoparticles (IONPs) to capture multiple LPrA2 peptides. We assessed the conjugation of LPrA2 to IONPs (IONPLPrA2) to determine the inhibitory effect on breast cancer cell growth and survival. Because LPrA2 decreases breast cancer tumor growth and chemotherapy is widely used in the treatment of breast cancer, we sought to assess if combining IONPLPrA2 and chemotherapeutic drugs would allow for reduction of the effective dose. Thus, we evaluated the survival of human breast cancer cell lines with IONPLPrA2 and a panel of anticancer drugs. 
MATERIALS AND METHODS

Reagents and antibodies
Nanoparticle conjugation
LPrA2 was synthesized as described [8, 19] . LPrA2 was de salted using the slidealyzer dialysis cassette (Thermo Fisher). LPrA2 was conjugated to IONPs (Ocean Nano tech) by the outlined method [20] .
Western blot analysis
IONPLPrA2 was separated by SDSPAGE. LPrA2 and LPrA2Scramble (Sc) were used as positive and negative controls, respectively. The peptides were transferred onto nitrocellulose membranes (BioRad). The membranes were probed with an LPrA2 antibody, purified from antigen injected rabbit bleeds. Anti rabbit IgG conjugated to horseradish peroxidase (Bio Rad) was used for further detection of the peptides. Chemiluminescent detection of the bands was displayed by Western blotting substrate (Thermo Fisher).
Nanoparticle tracking analysis
Dilutions of 1:10000 of the bound and unbound particles were sonicated for 30 min. The size and distribution of the conjugated and unconjugated IONPs were deter mined by the NanoSight (Malvern Instruments Ltd., Worcestershire, United Kingdom).
Cell culture
Human ER + MCF7 cells in addition to TNBC MDA MB231 and HCC1806 cells (American Type Culture Collection, ATCC, Manassas, VA) were cultured in DMEM (Thermo Fisher) with 10% FBS and 1% penicillin/ streptomycin (Thermo Fisher) and maintained in an incubator at 37 ℃ with 5% CO2. Immunoblotting analysis was performed as described [21] . The membranes were incubated with ObR, cyclin D1, pSTAT3, and STAT3 (Santa Cruz Biotechnology) antibodies overnight at 4 ℃. GAPDH (Sigma) was used as a protein loading control. Relative protein levels were determined by Image J software (National Institute of Health, NIH).
Cell lysis and immunoblotting analysis
Cell cycle analysis
Cells were seeded at 2 × 10 5 in 6 well cell culture plates and grown to 70%-80% confluence. They were treated with IONPLPrA2 at indicated (pmol/L) concentrations plus leptin (1.2 nmol/L for 2448 h. Leptin and un conjugated LPrA2 served as controls. The cells were trypsinized, washed with 1 × PBS, and resuspended in cold 100% methanol (Sigma). The were stored at 20 ℃ prior to analysis (< 1 wk). Afterward, the cells were centrifuged to remove the methanol. They were resuspended in 50 µL PI (Nexcelom) and incubated at 37 ℃ for 40 min. The cells were centrifuged to remove the PI, resuspended in 1 × PBS, and analyzed by the Nexcelom Cellometer Vision ® image based cytometer to determine the percentage of cells in the S phase of the cell cycle. 
MTT assay
Apoptosis assay
Cells were seeded at 2 × 10 5 in 6 well cell culture plates and grown to 70%-80% confluence. They were treated with the chemotherapeutic drugs: Cis (Millipore), CTX, PTX, and Dox (SelleckChem) in 5% FBS with or without 
Statistical analysis
All experiments were performed in triplicate. Oneway ANOVA (SigmaPlot) was used to determine statistical significance among treatment groups and controls. Data presented as the average ± standard deviation (SD). P values of P < 0.05 were considered statistically significant.
Biostatistics statement
The statistical review was performed by Ward Kirlin, 
RESULTS
Generation and characterization of IONP-LPrA2
The leptin antagonist, LPrA2, has been shown to inhibit breast cancer growth and progression in vitro as well as in vivo [2, 22, 23] . To increase its efficacy, LPrA2 was conjugated to IONPs. IONPs are amphiphilic and have a 10 nm core [20] . The binding of LPrA2 to IONPs was facilitated by EDAC, which activates the carboxyl group on the IONP surface and allows the formation of an amide bond with the amino group of LPrA2 ( Figure  1A ). To confirm the binding of the LPrA2 peptides to the nanoparticles, the conjugates were analyzed by SDSPAGE and Western blot. With LPrA2 antibody incubation, bands were detected at approximately 100 kD, indicating conjugated LPrA2, and approximately 3 kD indicating unbound LPrA2. Unconjugated LPrA2 and LPrA2Sc were used as positive and negative controls, respectively ( Figure 1B ). To further characterize IONP LPrA2, 1:10000 dilutions of the conjugated and uncon jugated IONPs were measured by NanoSight nano particle tracking analysis (Malvern); in which the left and right Yaxes show particle number and percent distribution, and the Xaxis displays particle size. The size of the unconjugated IONP was found to be 14 nm while conjugated IONPLPrA2 measured 20 nm. This data suggests that the conjugation of LPrA2 to IONPs was successful.
Ob-R expression and effect of IONP-LPrA2 on leptininduced pSTAT3 and cyclin D1 levels in human breast cancer cells
In order to determine the effects of IONPLPrA2 on leptin signaling inhibition, we first had to confirm expression of the leptin receptor, ObR, in the human breast can cer cell lines. Immunoprecipitation and subsequent Western blot analysis showed ObR expression in MDA MB231, HCC1806, and MCF7 cells ( Figure 2A ). Leptin signaling activates the JAK2/STAT3, MAPK/ERK, and PI3/Akt signaling pathways, which are implicated in its antiapoptotic activity [9] . For this reason, we aimed to determine the effect of IONPLPrA2 treatment on active/ phosphorylated, pSTAT3. Leptin significantly increased the level of pSTAT3 in MDAMB231 and HCC1806 cells. IONP-LPrA2 significantly inhibited the effect of leptin on pSTAT3 levels in HCC1806 cells. No significant changes occurred in pSTAT3 levels in MCF7 cells treated with leptin and IONPLPrA2 ( Figure 2B and C). Because leptin has been shown to increase cyclin D1 levels in breast cancer cells [14, 15] , we sought to determine the effect of IONPLPrA2 treatment on cyclin D1 expression in MDAMB231, HCC1806, and MCF7 breast cancer cells. Leptin significantly induced cyclin D1 expression in all cell lines ( Figure 2B and C). The addition of IONP LPrA2 significantly inhibited the effect of leptin on cyclin D1 expression in all cell lines ( Figure 2B and C). These results suggest that IONPLPrA2 abrogates the effect of leptin on leptininduced signaling pathways.
IONP-LPrA2 inhibits leptin-induced cell cycle progression of human breast cancer cell lines
Leptin has been shown to increase expression of the cell cycle associated protein, cyclin D1 [14, 15] . To illustrate the effect of leptin on cell cycle progression, the number of cells in the S phase was determined by cell cycle analysis with the Cellometer Vision (Nexcelom). MDAMB231, HCC1806, and MCF7 human breast cancer cells lines were treated with leptin (1.2 nmol/L) and IONPLPrA2 plus leptin in order to determine its antagonistic effect. The cells were treated with IONP LPrA2 concentrations ranging from 0.00180.036 pmol/ L. MDAMB231 and HCC1806 TNBC cell lines were treated for 24 h while the ER + MCF7 cells were treated for 48 h to produce an effect. Treatment with leptin caused a significant increase in cell cycle progression in HCC1806 ( Figure 3B ) and MCF7 ( Figure 3C ), but had no significant effect on MDA-MB-231 cells ( Figure 3A) . 
IONP-LPrA2 inhibits leptin-induced cell proliferation in human breast cancer cells
Leptin signaling stimulates breast cancer cell survival and proliferation [8] . To ascertain the manner in which IONPLPrA2 affects cell proliferation, an MTT assay was performed. MDAMB231, HCC1806, and MCF7 cell were treated with leptin (1.2 nmol/L) and IONPLPrA2 (0.0036) plus leptin (1.2 nmol/L). Leptin treatment significantly increased cell proliferation and IONP-LPrA2 significantly diminished the effect of leptin in all of the cell lines (Figure 4 ). This data indicates that IONPLPrA2 prevents leptin induction of cell proliferation.
IONP-LPrA2 decreases MDA-MB-231 tumorsphere formation
Selfrenewal is a hallmark of cancer. Leptin has been shown to increase selfrenewal and breast cancer stem cell (BCSC) growth [24] . To learn how IONPLPrA2 affects BCSC growth, tumorsphere formation was assessed. MDAMB231 TNBC cells were treated with leptin (1.2 nmol/L) and IONPLPrA2 (0.0036 pmol/L) plus leptin (1.2 nmol/L). Untreated, basal, MDAMB231 cells developed few small and medium tumorspheres (100200 µm), cells treated with leptin showed a significant increase in the development of medium (200 µm) and large tumorspheres (> 200 µm) in comparison to basal. Cells treated with IONPLPrA2 plus leptin displayed a significant decrease in medium tumorsphere growth relative to the leptin treated ( Figure 5 ). This data shows that IONPLPrA2 treatment may decrease BCSC growth.
The effect of chemotherapeutics on survival of breast cancer cell lines
Chemotherapy is among the most common treatments for breast cancer in addition to radiation and surgery [25] . To determine the effective dose of chemotherapeutics, cells were treated with a panel of anticancer drugs and viability was tested by the Annexin V FITC/PI Assay (Nexcelom). MDAMB231, HCC1806, and MCF7 cells were treated with Cis (0.0011.1 µmol/L), CTX (0.01100 µmol/L), Dox (0.0150 µmol/L), and PTX (0.051.0 µmol/L) for time periods ranging from 16 d to determine an effective dose to reduce cell viability ( Figure 6 ). Cis and Dox reduced cell viability in 24 h while CTX and PTX treated cells required up to 6 d to produce an effect. All cell lines displayed a similar response to Cis and PTX ( Figure 6A and D) . MDA MB231 cells appeared to be more sensitive to CTX and Dox ( Figure 6B and C) .
Determination of the effect of IONP-LPrA2 on survival of breast cancer cells treated with chemotherapeutics
Chemotherapy has many detrimental side effects; because of this it is advantageous to utilize adjuvant therapies in order to reduce the effective dose. To determine the adjuvant potential of IONPLPrA2, cells were treated with chemotherapeutics combined with IONPLPrA2 and analyzed for viability by the Annexin Figure 7) . Although cells were treated with PTX for up to 6 d to reduce cell viability, IONPLPrA2 showed no additional decrease in viability when combined with PTX ( Figure 7D ). PTX is an antimicrotubule agent which acts on the M phase of the cell cycle while the other chemotherapeutics act on DNA which affects the S phase [2] . This data suggests that IONPLPrA2 increases the potency of chemotherapeutics on TNBC cells, particularly anticancer drugs which target DNA.
DISCUSSION
In spite of methods for early detection of breast cancer, it remains the second leading cause of cancer deaths in women in the United States [1] . TNBC is a subtype of breast cancer characterized by the lack of hormone receptor expression. The absence of hormone receptors makes this more aggressive form of breast cancer even more difficult to treat. Obesity is often associated with poorer outcomes in individuals with breast cancer, particularly those with TNBC [25] . Obesity is characterized by an excess of the inflammatory cytokine, leptin. Elevated leptin levels display a significant correlation with metastasis and lower breast cancer patient survival [26] . The leptin antagonist, LPrA2 has been shown to inhibit leptin signaling in breast and other cancer types, but the actions of LPrA2 are restricted by its low MW of < 3 kD, short halflife, and insolubility in water [8, 27] . IONPLPrA2 was developed to circumvent these limitations. IONPs conjugated to other peptides, such as the amino terminal fragment of urokinase type plasminogen activator (ATFuPA) are stable for more than 48 h in in vivo imaging experiments [20] . IONPs are amphiphilic, small (10 nm core size), and uniformly sized to facilitate delivery which prevents phagocytosis [28] . The characteristics of IONPs make them an ideal delivery system for LPrA2 to target and treat breast cancer. In the present study, IONPLPrA2 was used to evaluate its ability to inhibit leptin signaling in human breast cancer cells. The data indicates that IONPLPrA2 abrogates cell cycle progression and acts as an adjuvant when administered with chemo therapeutics. Decreased levels of pSTAT3 and cyclin D1 with IONP LPrA2 treatment were shown by Western blot. Cyclin D1 is a cell cycle regulatory gene. STAT3 is a transcription factor responsible for the regulation of cyclin D1 [10] . Decreased levels of pSTAT3 with IONPLPrA2 treatment were seen at time points as early as 515 min post treatment. Previous studies have shown that leptin is mitogenic and increases cyclin D1 in ER + MCF7 breast cancer cells [14, 15] . Because leptin increases cyclin D1 and IONPLPrA2 inhibits the effect of leptin, utilizing agents that target cyclin D1 may be a plausible method to treat breast cancer. In this study, we have shown that IONP LPrA2 decreases pSTAT3 and cyclin D1. The decreased levels of these leptininduced targets may inhibit cell cycle progression in ER + MCF7 cells as well as MDA MB231 and HCC1806 TNBC cells. Inhibition of cell cycle progression by IONPLPrA2 was displayed by image based cytometry. Leptin has been shown to increase levels of cyclin D1 [14, 15] . In this study, we show that IONPLPrA2 decreases cyclin D1 expression, but the effect on cell cycle progression was yet to be determined. Here we show that IONPLPrA2 treatment decreases the percentage of cells in the S phase of the cell cycle, where DNA is synthesized, as or more effectively than LPrA2 alone. Interestingly, the greatest decrease in the percentage of cells in S phase with IONPLPrA2 treatment was seen in HCC1806 TNBC cells derived from a nonmetastatic squamous cell carcinoma in contrast to MCF7 and MDAMB231 cells derived from metastatic adenocarcinomas. This data suggests that IONPLPrA2 inhibition of cell cycle progression may reduce the advancement of breast cancer, and may be particularly beneficial in the treatment of nonmetastatic and squamous cell carcinomas.
Chemotherapy is the first line of treatment for TNBC. Although TNBC is generally more responsive to chemotherapy than other forms of breast cancer, there is an increased risk of developing drug resistance [29] . BCSC growth and selfrenewal play an important role in breast cancer drug resistance and leptin increases the risk [24] . These cells express molecular markers for breast cancer, CD44 + CD24 /ALDH + [10] . We have demonstrated that leptin induces in vitro BCSC, tumorsphere, forma tion and treatment with IONPLPrA2 attenuates the effect of leptin in MDAMB231 TNBC cells. These results indicate that IONPLPrA2 prevents BCSC formation and may decrease chemoresistance in TNBC.
Chemotherapeutic treatment of breast cancer is plagued with high toxicity. Toxic side effects and the development of drug resistance are cause for the development of adjuvant therapies. The need for adju vant therapies is exacerbated in TNBC patients who often experience relapse and develop resistance to chemotherapy [29] . TNBC is commonly treated with com bination chemotherapy [25] . Here, we treated breast cancer cells with a panel of commonly used chemothera peutics (Cis, CTX, Dox and PTX) in addition to IONP LPrA2 to test its ability to decrease cell viability more than the drugs alone. We demonstrated that TNBC cells, MDA-MB-231 displayed a significant decrease in viability with Cis and CTX plus IONPLPrA2; and HCC1806 showed a significant reduction in live cells when treated with Cis and Dox plus IONPLPrA2. ER + MCF7 cells treated with chemotherapeutics plus IONPLPrA2 did not show a significant decrease in viable cells. Also, there was no significant decrease in viability in the cells treated with PTX plus IONPLPrA2. This may be due, in part, to PTX's antimicrotubule action, which affects the M phase of the cell cycle [25] . Cis, CTX, and Dox act on DNA which affects the S phase [25] . These drugs may work synergistically with IONPLPrA2, which also appears to act on the S phase. These data indicate that IONPLPrA2 may act as a chemotherapeutic adjuvant by decreasing viability, thereby decreasing the effective dose in TNBC.
In conclusion, IONPLPrA2 was found to decrease the level of leptininduced targets pSTAT3 and cyclin D1. IONPLPrA2 decreased DNA synthesis during the S phase of the cell cycle and reduced proliferation in both ER + and TNBC cells. When combined with chemotherapeutics, particularly drugs targeting the S phase, IONPLPrA2 showed an additive effect on the reduction of live breast cancer cells. These findings indicate that IONPLPrA2 may be useful in the prevention of tumor cell growth and proliferation in breast cancer. Further, treatment with IONPLPrA2 may allow for lower chemotherapeutic dosing. These results are potentially beneficial for obese patients with elevated leptin levels, whom have a higher incidence and thus poorer outcome of TNBC. Taken together, the present data provides confirmation of our hypothesis that IONPLPrA2 treatment may be useful in impairing tumor growth and when given in combination with the indicated chemotherapeutics has the potential to increase drug effectiveness. These data indicate that there is a synergistic effect with IONPLPrA2 and chemo therapeutics which affect the S phase of the cell cycle in vitro.
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Background
Obesity and high leptin levels are strongly associated with breast cancer relapse, drug resistance, and poorer patient outcomes. Overexpression of leptin and its receptor, Ob-R, induce breast cancer cell growth and proliferation. Triple negative breast cancer (TNBC) is a subtype of breast cancer which comprises approximately 15% of cases and is an aggressive form of the disease with no targeted therapy. TNBC chemotherapeutic treatment often leads to chemoresistance and shows several undesirable side effects. Leptin is proliferative and is a survival factor for breast cancer treated with chemotherapeutics. Therefore, the authors have developed a leptin peptide receptor antagonist coupled to iron oxide nanoparticles (IONP-LPrA2), which successfully inhibits leptin signaling as well as increases chemotherapeutic effectiveness in breast cancer and is particularly promising for TNBC treatment.
Research frontiers
IONP-LPrA2 could be a new and effective biological for blocking pro-oncogenic and drug resistance effects of leptin in breast cancer, especially in obese patients suffering from TNBC that are treated with chemotherapeutics.
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This study describes for the first time the production and characterization of a new biological bound to nanoparticles that can effectively block leptin signaling inducing proliferation and survival in breast cancer cells treated with chemotherapeutics.
Applications
In recent years, IONPs have become an important tool for biomedical applications. The use IONPs has been employed in vaccinations, drug delivery, MRI, and molecular imaging. The authors' data suggests combining IONPs with the leptin antagonist, LPrA2, prevents the growth of breast cancer cells and acts as a chemotherapeutic adjuvant by reducing the effective dose.
Terminology
Leptin signaling occurs when the hormone is secreted by the adipose tissue and binds to its receptor, Ob-R. Breast cancer, particularly in obese individuals, is associated with high levels of leptin. Leptin signaling leads to increased breast cancer cell growth, proliferation and drug resistance. The inhibition of leptin signaling with the nanoparticle-linked leptin antagonist, IONP-LPrA2, provides a promising new way to improve breast cancer chemotherapy.
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